|
1
|
Brockmeyer C and Seidl A: Binocrit:
Assessment of quality, safety and efficacy of biopharmaceuticals.
Eur J Hosp Pharm Pract. 15:34–40. 2009.
|
|
2
|
Weigang-Köhler K, Vetter A and
Thyroff-Friesinger U: HX575, recombinant human epoetin alfa, for
the treatment of chemotherapy-associated symptomatic anaemia in
patients with solid tumours. Onkologie. 32:168–174. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haag-Weber M, Vetter A and
Thyroff-Friesinger U: INJ-Study Group: Therapeutic equivalence,
long-term efficacy and safety of HX575 in the treatment of anemia
in chronic renal failure patients receiving hemodialysis. Clin
Nephrol. 72:380–390. 2009.PubMed/NCBI
|
|
4
|
Bowen D, Culligan D, Jowitt S, Kelsey S,
Mufti G, Oscier D and Parker J: UK MDS Guidelines Group: Guidelines
for the diagnosis and therapy of adult myelodysplastic syndromes.
Br J Haematol. 120:187–200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Greenberg PL, Attar E, Bennett JM, et al:
National Comprehensive Cancer Network: NCCN clinical practice
guidelines in oncology: Myelodysplastic syndromes. J Natl Compr
Canc Netw. 9:30–56. 2011.PubMed/NCBI
|
|
6
|
Valent P, Horny HP, Bennett JM, et al:
Definitions and standards in the diagnosis and treatment of the
myelodysplastic syndromes: Consensus statements and report from a
working conference. Leuk Res. 31:727–736. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rizzo JD, Somerfield MR, Hagerty KL, et
al: Use of epoetin and darbepoetin in patients with cancer: 2007
American Society of Hematology/American Society of Clinical
Oncology clinical practice guideline update. Blood. 111:25–41.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alessandrino EP, Amadori S, Barosi G, et
al: Italian Society of Hematology: Evidence- and consensus-based
practice guidelines for the therapy of primary myelodysplastic
syndromes. A statement from the Italian Society of Hematology.
Haematologica. 87:1286–1306. 2002.PubMed/NCBI
|
|
9
|
Santini V, Alessandrino PE, Angelucci E,
et al: Italian Society of Hematology: Clinical management of
myelodysplastic syndromes: Update of SIE, SIES, GITMO practice
guidelines. Leuk Res. 34:1576–1588. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stebler C, Tichelli A, Dazzi H, Gratwohl
A, Nissen C and Speck B: High-dose recombinant human erythropoietin
for treatment of anemia in myelodysplastic syndromes and paroxysmal
nocturnal hemoglobinuria: A pilot study. Exp Hematol. 18:1204–1208.
1990.PubMed/NCBI
|
|
11
|
Bessho M, Jinnai I, Matsuda A, Saito M and
Hirashima K: Improvement of anemia by recombinant erythropoietin in
patients with myelodysplastic syndromes and aplastic anemia. Int J
Cell Cloning. 8:445–458. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schouten HC, Vellenga E, van Rhenen DJ, de
Wolf JT, Coppens PJ and Blijham GH: Recombinant human
erythropoietin in patients with myelodysplastic syndromes.
Leukemia. 5:432–436. 1991.PubMed/NCBI
|
|
13
|
Hellström E, Birgegård G, Lockner D,
Helmers C, Ost A and Wide L: Treatment of myelodysplastic syndromes
with recombinant human erythropoietin. Eur J Haematol. 47:355–360.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stein RS, Abels RI and Krantz SB:
Pharmacologic doses of recombinant human erythropoietin in the
treatment of myelodysplastic syndromes. Blood. 78:1658–1663.
1991.PubMed/NCBI
|
|
15
|
Jӓdersten M, Montgomery SM, Dybedal I,
Porwit-MacDonald A and Hellström-Lindberg E: Long-term outcome of
treatment of anemia in MDS with erythropoietin and G-CSF. Blood.
106:803–811. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park S, Grabar S, Kelaidi C, et al: GFM
group (Groupe Francophone des Myélodysplasies): Predictive factors
of response and survival in myelodysplastic syndrome treated with
erythropoietin and G-CSF: The GFM experience. Blood. 111:574–582.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hellström-Lindberg E: Efficacy of
erythropoietin in the myelodysplastic syndromes: A meta-analysis of
205 patients from 17 studies. Br J Haematol. 89:67–71. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Greenberg PL, Sun Z, Miller KB, et al:
Treatment of myelodysplastic syndrome patients with erythropoietin
with or without granulocyte colony-stimulating factor: Results of a
prospective randomized phase 3 trial by the Eastern Cooperative
Oncology Group (E1996). Blood. 114:2393–2400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morra E, Lazzarino M, Castello A, et al:
Risk assessment in myelodysplastic syndromes: Value of clinical,
hematologic and bone marrow histologic findings at presentation.
Eur J Haematol. 45:94–100. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greenberg PL, Sanz GF and Sanz MA:
Prognostic scoring systems for risk assessment in myelodysplastic
syndromes. Forum (Genova). 9:17–31. 1999.PubMed/NCBI
|
|
21
|
Cheson BD, Greenberg PL, Bennett JM, et
al: Clinical application and proposal for modification of the
International Working Group (IWG) response criteria in
myelodysplasia. Blood. 108:419–425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Symeonidis A, Kouraklis-Symeonidis A,
Zikos P, et al: Factor predicting for a favorable response among
patients with myelodysplastic syndromes treated with erythropoietin
± G-CSF. Leuk Res. 31:S116–S117. 2001. View Article : Google Scholar
|
|
23
|
Santini V: Clinical use of erythropoietic
stimulating agents in myelodysplastic syndromes. Oncologist.
16:(Suppl 3). S35–S42. 2011. View Article : Google Scholar
|
|
24
|
Andrews NC: Anemia of inflammation: The
cytokine-hepcidin link. J Clin Invest. 113:1251–1253. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hedenus M, Birgegård G, Nӓsman P, Ahlberg
L, Karlsson T, Lauri B, Lundin J, Lӓrfars G and Osterborg A:
Addition of intravenous iron to epoetin beta increases hemoglobin
response and decreases epoetin dose requirement in anemic patients
with lymphoproliferative malignancies: A randomized multicenter
study. Leukemia. 21:627–632. 2007.PubMed/NCBI
|
|
26
|
Auerbach M, Ballard H, Trout JR, McIlwain
M, Ackerman A, Bahrain H, Balan S, Barker L and Rana J: Intravenous
iron optimizes the response to recombinant human erythropoietin in
cancer patients with chemotherapy-related anemia: A multicenter,
open-label, randomized trial. J Clin Oncol. 22:1301–1307. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Henry DH, Dahl NV, Auerbach M,
Tchekmedyian S and Laufman LR: Intravenous ferric gluconate
significantly improves response to epoetin alfa versus oral iron or
no iron in anemic patients with cancer receiving chemotherapy.
Oncologist. 12:231–242. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Auerbach M: Should intravenous iron be the
standard of care in oncology? J Clin Oncol. 26:1579–1581. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giordano G, Mondello P, Tambaro R, de
Maria M, d'Amico F, Sticca G and di Falco C: Intravenous iron
support vs oral liposomal iron support in patients with refractory
anemia treated with Epo alpha. Monocentric prospective study. Leuk
Res. 35:S1372011. View Article : Google Scholar
|
|
30
|
Mare M, Mafodda A, Prestifilippo A, et al:
Assessment of safetyand efficacy of oral liposomal iron
supplemented in cancer patients with chemotherapy related anemia
receiving epoetin alfa. TUMORI. 11:(Suppl 1). S1182011.(In
Italian).
|
|
31
|
Stasi R, Brunetti M, Terzoli E, Abruzzese
E and Amadori S: Once-weekly dosing of recombinant human
erythropoietin alpha in patients with myelodysplastic syndromes
unresponsive to conventional dosing. Ann Oncol. 15:1684–1690. 2004.
View Article : Google Scholar : PubMed/NCBI
|
